
Stefan Duensing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1360399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene, 2001, 20, 7888-7898.	5.9	539
2	Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. International Journal of Cancer, 2004, 109, 157-162.	5.1	292
3	The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Research, 2002, 62, 7075-82.	0.9	292
4	Multiparametric Magnetic Resonance Imaging (MRI) and MRI–Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. European Urology, 2016, 70, 846-853.	1.9	258
5	The Forkhead-associated Domain Protein Cep170 Interacts with Polo-like Kinase 1 and Serves as a Marker for Mature Centrioles. Molecular Biology of the Cell, 2005, 16, 1095-1107.	2.1	215
6	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer—Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. European Urology, 2017, 72, 888-896.	1.9	136
7	Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene, 2002, 21, 6241-6248.	5.9	107
8	Human Papillomavirus Type 16 E7 Oncoprotein Can Induce Abnormal Centrosome Duplication through a Mechanism Independent of Inactivation of Retinoblastoma Protein Family Members. Journal of Virology, 2003, 77, 12331-12335.	3.4	106
9	Genomic instability and cancer: Lessons learned from human papillomaviruses. Cancer Letters, 2011, 305, 113-122.	7.2	93
10	Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. Journal of Nuclear Medicine, 2017, 58, 1805-1810.	5.0	91
11	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clinical Cancer Research, 2017, 23, 1829-1840.	7.0	74
12	Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004, 23, 8206-8215.	5.9	69
13	Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes. Journal of Nuclear Medicine, 2020, 61, 683-688.	5.0	61
14	Cullin 1 Functions as a Centrosomal Suppressor of Centriole Multiplication by Regulating Polo-like Kinase 4 Protein Levels. Cancer Research, 2009, 69, 6668-6675.	0.9	57
15	Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology, 2008, 372, 157-164.	2.4	52
16	Centrosomes, Genomic Instability, and Cervical Carcinogenesis. Critical Reviews in Eukaryotic Gene Expression, 2003, 13, 9-23.	0.9	50
17	CAND1 Promotes PLK4-Mediated Centriole Overduplication and Is Frequently Disrupted in Prostate Cancer. Neoplasia, 2012, 14, 799-806.	5.3	48
18	Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environmental and Molecular Mutagenesis, 2009, 50, 741-747.	2.2	46

#	Article	IF	CITATIONS
19	A tentative classification of centrosome abnormalities in cancer. Cell Biology International, 2005, 29, 352-359.	3.0	45
20	Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nature Communications, 2016, 7, ncomms11845.	12.8	44
21	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease—A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. European Urology Focus, 2020, 6, 1205-1212.	3.1	39
22	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	4.2	38
23	Centrosomes, Polyploidy and Cancer. Advances in Experimental Medicine and Biology, 2010, 676, 93-103.	1.6	33
24	Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers. Biochemical Pharmacology, 2010, 80, 575-583.	4.4	32
25	The Impact of Magnetic Resonance Imaging on Prediction of Extraprostatic Extension and Prostatectomy Outcome in Patients with Low-, Intermediate- and High-Risk Prostate Cancer: Try to Find a Standard. Journal of Endourology, 2015, 29, 1396-1405.	2.1	32
26	Mutations in BRCA2 and taxane resistance in prostate cancer. Scientific Reports, 2017, 7, 4574.	3.3	32
27	Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphoma. Molecular Cancer, 2003, 2, 30.	19.2	31
28	Human papillomaviruses in urological malignancies: A critical assessment. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e19-46.e27.	1.6	30
29	High-risk prostate cancer: A disease of genomic instability. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1101-1107.	1.6	29
30	Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Progress in Cell Cycle Research, 2003, 5, 383-91.	0.9	29
31	Daughter Centriole Elongation Is Controlled by Proteolysis. Molecular Biology of the Cell, 2010, 21, 3942-3951.	2.1	28
32	A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention. Molecular Cancer, 2010, 9, 153.	19.2	28
33	The centrosome as potential target for cancer therapy and prevention. Expert Opinion on Therapeutic Targets, 2013, 17, 43-52.	3.4	28
34	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. European Urology Focus, 2021, 7, 102-110.	3.1	28
35	The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. Oncotarget, 2016, 7, 418-432.	1.8	28
36	Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. International Journal of Cancer, 2016, 139, 2359-2369.	5.1	27

#	Article	IF	CITATIONS
37	Correlation between genomic index lesions and mpMRI and 68Ca-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	3.3	27
38	Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 161.e19-161.e30.	1.6	26
39	<i>TMPRSS2:ERG</i> gene fusion variants induce TGF·l ² signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget, 2017, 8, 25115-25130.	1.8	23
40	FGF-2 Disrupts Mitotic Stability in Prostate Cancer through the Intracellular Trafficking Protein CEP57. Cancer Research, 2013, 73, 1400-1410.	0.9	22
41	Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbeck's Archives of Surgery, 2017, 402, 637-644.	1.9	22
42	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. International Journal of Cancer, 2017, 141, 1643-1653.	5.1	21
43	Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Frontiers in Medicine, 2017, 4, 157.	2.6	21
44	Genomic features of renal cell carcinoma with venous tumor thrombus. Scientific Reports, 2018, 8, 7477.	3.3	19
45	<scp>PBRM1</scp> (<scp>BAF180</scp>) protein is functionally regulated by p53â€induced protein degradation in renal cell carcinomas. Journal of Pathology, 2015, 237, 460-471.	4.5	18
46	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 2020, 295, 15636-15649.	3.4	18
47	Adjuvant therapy for renal-cell carcinoma: settled for now. Lancet, The, 2016, 387, 1973-1974.	13.7	17
48	MERTK as a novel therapeutic target in head and neck cancer. Oncotarget, 2016, 7, 32678-32694.	1.8	17
49	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clinical Genitourinary Cancer, 2015, 13, e145-e152.	1.9	16
50	Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma. Neoplasia, 2014, 16, 1028-1035.	5.3	15
51	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	1.8	14
52	FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 365.e15-365.e26.	1.6	12
53	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ⁻ve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
54	Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms. Genes and Cancer, 2010, 1, 883-892.	1.9	11

#	Article	IF	CITATIONS
55	Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma1Present address: Department of Urology, University Hospital Frankfurt, Germany.2Equal contributions Urologic Oncology: Seminars and Original Investigations, 2014, 32, 877-884.	1.6	11
56	Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27 ^{Kip1} : Implications for Spatial Niche Formation and Functional Intratumoral Heterogeneity. Pathobiology, 2020, 87, 114-124.	3.8	11
57	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	2.8	10
58	The ERG-Regulated <i>LINC00920</i> Promotes Prostate Cancer Cell Survival via the 14-3-3ïµâ€"FOXO Pathway. Molecular Cancer Research, 2020, 18, 1545-1559.	3.4	10
59	Antibody selection influences the detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100186.	1.7	10
60	Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Translational Oncology, 2015, 8, 487-496.	3.7	9
61	The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal—Implications for targeted therapies1Equal contributions Urologic Oncology: Seminars and Original Investigations, 2015, 33, 72.e1-72.e7.	1.6	9
62	Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 32.e9-32.e16.	1.6	9
63	Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis, 2019, 8, 4.	4.9	9
64	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Scientific Reports, 2021, 11, 14244.	3.3	9
65	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	1.6	8
66	Analysis of centrosomes in human cancer. Methods in Cell Biology, 2015, 129, 51-60.	1.1	7
67	Evolution of Salvage Radical Prostatectomy from Open to Robotic and Further to Retzius Sparing Surgery. Journal of Clinical Medicine, 2022, 11, 202.	2.4	7
68	Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget, 2010, 1, 6-8.	1.8	6
69	Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget, 2010, 1, 6-8.	1.8	6
70	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers, 2021, 13, 964.	3.7	5
71	Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines, 2021, 9, 627.	3.2	5
72	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	2.8	5

#	Article	IF	CITATIONS
73	Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications. Translational Oncology, 2015, 8, 480-486.	3.7	4
74	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. Cancers, 2021, 13, 1623.	3.7	4
75	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. Future Science OA, 2018, 4, FSO299.	1.9	3
76	Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. , 0, .		3
77	Using PSMA (prostate-specific membrane antigen) evaluation on prostate biopsies for risk stratification at time of initial diagnosis Journal of Clinical Oncology, 2019, 37, 6-6.	1.6	3
78	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. Journal of Cancer, 2017, 8, 507-512.	2.5	2
79	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	1.6	2
80	Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies. Biomedicines, 2020, 8, 585.	3.2	2
81	<scp>PARP</scp> inhibition in prostate cancer. Genes Chromosomes and Cancer, 2021, 60, 344-351.	2.8	2
82	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. Frontiers in Oncology, 2022, 12, .	2.8	2
83	A Platform and Multisided Market for Translational, Software-Defined Medical Procedures in the Operating Room (OP 4.1): Proof-of-Concept Study. JMIR Medical Informatics, 2022, 10, e27743.	2.6	1
84	Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period. Urologia Internationalis, 2022, 106, 1158-1167.	1.3	1
85	Human Papillomavirus Infection and Centrosome Anomalies in Cervical Cancer. , 2005, , 353-370.		0
86	Detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 28, 100230.	1.7	0
87	Clinical factors predictive for efficacy of treatment with cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) in second and later lines Journal of Clinical Oncology, 2016, 34,	1.6	0